The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results.
 
Nitin Ohri
Consulting or Advisory Role - Genentech; Merck
Research Funding - AstraZeneca; Merck (Inst); Reflexion Medical (Inst)
 
Shruti Jolly
Honoraria - Varian Medical Systems
Consulting or Advisory Role - AstraZeneca; Varian Medical Systems
 
Benjamin T. Cooper
No Relationships to Disclose
 
Rafi Kabarriti
No Relationships to Disclose
 
William Raymond Bodner
No Relationships to Disclose
 
Jonathan Klein
No Relationships to Disclose
 
Shankar Viswanathan
No Relationships to Disclose
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Genentech; Janssen
Research Funding - Delfi Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Nektar
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Medscape; Navire; Pfizer; Regeneron; Takeda
 
Haiying Cheng
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - Roche/Genentech; Spectrum Pharmaceuticals; Vaccinex; Vaccinex
Patents, Royalties, Other Intellectual Property - Pat pending
 
Rasim A. Gucalp
Honoraria - Merck
 
Enrico Castellucci
No Relationships to Disclose
 
Angel Qin
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Takeda (Inst); Xencor (Inst)
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Genentech/Roche; Janssen Oncology; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Merck
Other Relationship - AstraZeneca
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); BeiGene; Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology; GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)